The antitumor immune responses induced by nanoemulsionencapsulated MAGE1-HSP70/SEA complex protein vaccine following different administration routes

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 915-920

  Ge, Wei ^a,b   Hu, Pei Zhen ^a   Huang, Yang ^a   Wang, Xiao Ming ^b   Zhang, Xiu Min ^a   Sun, Yu Jing ^a   Li, Zeng Shan ^a   Si, Shao Yan ^a   Sui, Yan Fang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Nanoemulsion; Peroral route; Tumor vaccin

Indexed keywords

HEAT SHOCK PROTEIN 70; LACTATE DEHYDROGENASE; MELANOMA ANTIGEN 1; STAPHYLOCOCCUS ENTEROTOXIN A; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY TEST; ECHOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME RELEASE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; EMULSIONS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HSP70 HEAT-SHOCK PROTEINS; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOTECHNOLOGY; RECOMBINANT FUSION PROTEINS;

EID: 70350352530     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000517     Document Type: Article

References (33)

1. Sudo T, Kuramoto T, Komiya S, et al: Expression of MAGE genes in osteosarcoma. J Orthop Res 15: 128-132, 1997.
2. Ma JH, Sui YF, Ye J, et al: Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 54: 907-914, 2005.
3. Torres BA, Kominsky SL, Perrin GQ, et al: Superantigens: the good, the bad, and the ugly. Exp Biol Med 226: 164-176, 2001.
4. Fleischer B and Schrezenmeier H: T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 167: 1697-1707, 1988.
5. Ge W, Sui YF, Wu DC, et al: MAGE-1/Heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo. Cancer Immunol Immunother 55: 841-849, 2006.
6. Ye J, Chen GS, Song HP, et al: Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother 53: 825-834, 2004.
7. Melief CJ and Kast WM: T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145: 167-177, 1995.
8. Alpar HO, Field WN, Hayes K and Lewis DA: A possible use of orally administered microspheres in the treatment of inflammation. J Pharm Pharmacol 41: 50-53, 1989.
9. Ammoury N, Fessi H, Devissaguet JP, et al: Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly (D, L-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res 8: 101-105, 1991.
10. Beck PH, Kreuter J, Müller WEG and Schatton W: Improved peroral delivery of avarol with polyalkylcyanoacrylate nanoparticles. Eur J Pharm Biopharm 40: 134-137, 1994.
11. Bonduelle S, Carrier M, Pimienta C, et al: Tissue concentration of nanoencapsulated radiolabelled cyclosporin following peroral delivery in mice or ophthalmic applications in rabbits. Eur J Pharm Biopharm 42: 313-319, 1996.
12. Damgé C, Aprahamian M, Balboni G, et al: Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int J Pharm 36: 121-125, 1987.
13. Damgé C, Michel C, Aprahamian M, et al: Nanocapsules as carriers for oral peptide delivery. J Control Release 13: 233-239, 1990.
14. Damgé C, Michel C, Aprahamian M and Couvreur P: New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37: 246-251, 1988.
15. Damgé C, Vonderscher J, Marbach P and Pinget M: Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J Pharm Pharmacol 49: 949-954, 1997.
16. Hubert B, Atkinson J, Guerret M, et al: The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm Res 8: 734-738, 1991.
17. Maincent P, Le Verge R, Sado P, et al: Deposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J Pharm Sci 75: 955-958, 1986.
18. Mathiowitz E, Jacob JS, Jong YS, et al: Biologically erodible microspheres as potential oral drug delivery systems. Nature 386: 410-414, 1997.
19. Ottenbrite R, Zhao R and Milstein S: A new oral microsphere drug delivery system. Macromol Symp 101: 379-387, 1996.
20. Ponchel G and Irache JM: Specific and non-specific bio-adhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 34: 191-219, 1998.
21. Niidome T and Huang L: Gene therapy progress and prospects: non-viral vectors. Gene Ther 9: 1647-1652, 2002.
22. Vinogradov SV, Bronich TK and Kabanov AV: Nanosized cationic hydrogels for drug delivery: Preparation, properties and interactions with cells. Adv Drug Deliv Rev 54: 135-147, 2002.
23. Jores K, Mehnert W, Drechsler M, et al: Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 95: 217-227, 2004.
24. Sarciaux JM, Acar L and Sado PA: Using microemulsion formulations for drug delivery of therapeutic peptides. Int J Pharm 120: 127-136, 1995.
25. Constantinides PP, Lancaster CM, Marcello J, et al: Enhanced intestinal absorption of an RGD peptide from water-in-oil microemulsions of different composition and particle size. J Control Rel 34: 109-116, 1995.
26. Constantinides P: Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 12: 1561-1572, 1995.
27. Constantinides PP, Scalart JP, Lancaster S, et al: Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res 11: 1385-1390, 1994.
28. Pouton CW: Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 25: 47-58, 1997.
29. Swenson EC and Curatolo WJ: Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv Rev 8: 39-92, 1992.
30. Swenson ES, Milisen WB and Curatolo W: Intestinal permeability enhancement: efficacy, acute local toxicity and reversibility. Pharm Res 11: 1132-1142, 1994.
31. Pappo J and Ermak TH: Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. Clin Exp Immunol 76: 144-148, 1989.
32. O'Hagan DT: Intestinal translocation of particulates - implications for drug and antigen delivery. Adv Drug Deliv Rev 5: 265-285, 1990.
33. Devissaguet JP, Fessi H, Ammoury N and Barratt G: Colloidal drug delivery systems for gastrointestinal application. In: Drug Targeting and Delivery-Concepts in Dosage Form Design. Junginger HE (ed). Ellis Horwood, New York, pp71-91, 1992.